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Abstract Lipases form Candida rugosa and Candida antarctica were tested for their appli-
cation in the enzymatic kinetic resolution of (R,S)-flurbiprofen by enantioselective esterifica-
tion. Successful chromatographic separation with well-resolved peaks of (R)- and (S)-
flurbiprofen and their esters was achieved in one run on chiral stationary phases by high-
performance liquid chromatography (HPLC). In this study screening of enzymes was per-
formed, and Novozym 435 was selected as an optimal catalyst for obtaining products with high
enantiopurity. Additionally, the influence of organic solvents (dichloromethane, dichloroethane,
dichloropropane, and methyl tert-butyl ether), primary alcohols (methanol, ethanol, n-propanol,
and n-butanol), reaction time, and temperature on the enantiomeric ratio and conversion was
tested. The high values of enantiomeric ratio (E in the range of 51.3–90.5) of the esterification
of (R,S)-flurbiprofen were obtained for all tested alcohols using Novozym 435, which have a
great significance in the field of biotechnological synthesis of drugs. The optimal temperature
range for the performed reactions was from 37 to 45 °C. As a result of the optimization, (R)-
flurbiprofen methyl ester was obtained with a high optical purity, eep=96.3 %, after 96 h of
incubation. The enantiomeric ratio of the reaction was E=90.5 and conversion was C=35.7 %.
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Introduction
Flurbiprofen [2-(2-fluoro-4-biphenyl)-propionic acid] is a nonsteroidal anti-inflammatory drug
of the 2-arylpropionic acid class and has a chiral center. It exists in two enantiomeric forms:
(R,S)-flurbiprofen is currently administered as a racemic mixture, but the enantiomers of this
anti-inflammatory agent are characterized by different pharmacological activities [1–3]. (S)-
flurbiprofen is responsible for the inhibition of the activity of cyclooxygenase Cox-2 as an
anti-inflammatory effect and also the inhibition of Cox-1, which causes gastrointestinal side
effects after long-term use. In contrast, (R)-flurbiprofen is inactive on both forms of cycloox-
ygenase and is in vivo inefficiently converted into the (S)-form. Therefore, it might not cause
the gastrointestinal and renal side effects which are characteristic for other NSAIDs [4–6].
Recent studies show that (R)-flurbiprofen has antinociceptive properties, inhibits in vivo the
progression of colon and prostate cancer in various animal models, and also inhibits in vitro
the survival of colon and prostate cancer cell lines. Important is that the inhibition of the Cox
enzymes is not considered as the pharmacological mechanism of the activity of the (R)-
enantiomer. Furthermore, it has been shown that this enantiomer has a significant antiprolif-
erative activity [7–11].
Lipases are the most widely used class of enzymes in chemistry and biotechnology.
Presently, these enzymes are useful in organic synthesis and kinetic resolution of racemic
compounds. The lipase from Candida rugosa and the isoform B of the lipase from Candida
antarctica are commonly used members of the lipase-group enzymes [12–18]. The active
center of the lipase builds a specific environment that allows distinguishing between the
enantiomers. Different studies have proven that lipases perform at the interface between
hydrophobic and hydrophilic regions, and the water content is an important factor affecting
their enantioselectivity. A small amount of water is needed to retain their active three-
dimensional conformation state, stability, and active site polarity. Moreover, it should be
considered that lipases “tolerate” a large number of non-natural substrates, are stable and
active in organic solvents without co-factors, and are commercially available in free and
immobilized forms [19–31].
Novozym 435, an immobilized lipase B from C. antarctica (CAL-B), is produced by
submerged fermentation on a genetically modified Aspergillus microorganism and is
immobilized by physical adsorption on the macroporous resin Lewatit VP OC 1600; a
poly(metacrylic acid) cross-linked with divinylbenzene (DVB). The loading of enzyme
(CAL-B) onto the support ranges between 8.5 and 20 % (w/w). Novozym 435 has an
outstanding activity and stability in hydrophobic organic media. However, due to enzyme
displacement or leaching, multiple reuse cycles of Novozym 435 are often unfeasible. From a
pharmaceutical point of view, well-documented high catalytic activity of Novozym 435 is
important, because of the possibility to use this enzyme for the synthesis of selected isomer of
a chiral drug [32–38].
The separation of enantiomers and determination of enantiomeric purity of chiral com-
pounds are a significant issue in chemical and pharmaceutical analysis. Among the techniques
used for chiral separations, such as gas chromatography (GC), supercritical fluid chromatog-
raphy (SFC), capillary electrophoresis (CE), and capillary electrochromatography (CEC), the
most popular is high-performance liquid chromatography (HPLC) with chiral stationary phases
(CSPs). This technique allows separating and determining the enantiomeric purity of many chiral
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compounds in a simple, efficient, and convenient way. To date, chiral stationary phases based on
derivatized polysaccharides, such as cellulose- and amylose derivatives, are the most widely used in
liquid chromatography because of their broad enantioselectivity. As mentioned in many reports,
cellulose tris(3,5-dimethylphenylcarbamate), amylose tris(3,5-dimethylphenylcarbamate), and
cellulose tris(4-methylbenzoate) stationary phases have the ability to chirally resolve more than
80 % of the drugs currently available on the market [39–43].
In the present work, the lipase-catalyzed kinetic resolution of (R,S)-flurbiprofen has been
studied. The optimization of the enzymatic enantioselective esterification was evaluated from
the separation with chiral stationary phases. The activity of lipases from C. rugosa and
C. antarctica as potential enzymatic catalysts in the enantioselective esterification of (R,S)-
flurbiprofen was assessed. Additionally, the influences of temperature, solvents as a reaction
medium, alcohol moiety, and reaction time were tested on the conversion and enantiomeric
ratio of the lipase-catalyzed reactions. The obtained chiral products were analyzed on the chiral
stationary phases. The optimization of the chromatographic conditions, such as the selection of
stationary and mobile phases, flow rate, temperature, and volume of the injected analytes,
allowed obtaining well-resolved peaks of both substrates and products during one chromato-
graphic analysis. The proposed chromatographic separation of (R)- and (S)-flurbiprofen and
their esters within one run was performed in the normal phase conditions on the
polysaccharide-based chiral stationary phase—Lux Cellulose-3.
Materials and Methods
Chemicals
(R,S)-Flurbiprofen, (R)-flurbiprofen, n-heptane, 2-propanol (IPA), C. antarctica lipase B
(Novozym 435), lipase B C. antarctica (recombinant from Aspergillus oryzae, powder, beige,
~9 U/mg, CAL-B), lipase CRL type VII from C. rugosa (activity ≥700 units/mg solid), and
trifluoroacetic acid were purchased from Sigma-Aldrich (Steinheim, Germany). Lipases OF
and MY from C. rugosa (activity 380,000 and 32,000 U/g solid, respectively) were gifts from
Meito Sangyo (Nagoya, Japan). Methyl tert-butyl ether (MtBE), dichloromethane (DCM),
dichloroethane (DCE), dichloropropane (DCP), methanol, ethanol, n-propanol, n-butanol, and
molecular sieves 4 Å were purchased from POCH (Gliwice, Poland). The (R)- and (S)-esters of
flurbiprofen were obtained as products of a standard esterification reaction of (R,S)-
flurbiprofen and (R)-flurbiprofen with appropriate alcohols (methanol, ethanol, n-propanol,
and n-butanol) using sulfuric acid (H2SO4) as catalyst [44]. The water used in the study was
prepared with a Milli-Q Water Purification System (Millipore, Bedford, MA, USA). All
incubations were performed at adjusted temperatures (20, 30, 37, and 45 °C) and a fixed
number of rotations (600 rpm) in Thermomixer comfort (Eppendorf, Hamburg, Germany).
Instrumentation
The Shimadzu HPLC system (Japan) used was equipped with a pump, model LC-20AD; a
UV-VIS detector, model SPD-20A; a degasser, model DGU-20A5; an autosampler, model
SIL-20ACHT; and a column oven, model CTO-10ASVP. A Lux Cellulose-1 (LC-1) (4.6 mm×
250 mm ) column with cellulose tris(3,5-dimethylphenylcarbamate) as chiral selector, a Lux
Cellulose-2 (LC-2) (4.6 mm×250 mm) column with cellulose tris(3-chloro-4-
methylphenylcarbamate) as chiral selector, a Lux Cellulose-3 (LC-3) (4.6 mm×250 mm)
column with cellulose tris(4-methylbenzoate) as chiral selector, a Lux Amylose-2 (LA-2)
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(4.6 mm×250 mm) column with amylose tris(5-chloro-2-methylphenylcarbamate) as chiral
selector, and a Guard Cartridge System model KJO-4282 were purchased from Phenomenex
(Torrance, CA, USA). All columns had 5 μm particle sizes.
Chromatographic Conditions
The most appropriate chromatographic conditions for separation of (R)- and (S)-flurbiprofen
and their esters were a mobile phase composed of n-heptane/2-propanol/trifluoroacetic acid
(96.5/3.5/0.2 v/v/v) at a flow rate of 1 mL/min. Four types of chiral stationary phases were
tested, Lux Cellulose-1, Lux Cellulose-2, Lux Cellulose-3, and Lux Amylose-2, with respect
to the resulting peak shapes and the chiral resolutions. The Lux Cellulose-3 HPLC column was
chosen as the optimal one for the separation of (R)- and (S)-flurbiprofen and their esters. The
chromatographic process was operated at 15 °C. The UV detection wavelength was set at
254 nm. The enantiomeric excesses of the substrate (ees) and the product (eep) as well as the
conversion (C), enantiomeric ratio (E) (also called enantioselectivity), and resolution values
(Rs) were calculated using the equations described in the literature [45–47].
The E was calculated as follows:
E ¼ In 1−cð Þ 1−eesð Þ½ 
In 1−cð Þ 1þ eesð Þ½  ð1Þ
The ees and eep values were determined as follows:
ees ¼ R−SRþ S ð2Þ
eep ¼ R−SRþ S ð3Þ
For R>S
where S and R represent the chromatographic peak areas of the S- and R-enantiomers,
respectively. The quantities of flurbiprofen and its esters were expressed by the value of the
chromatographic peak areas.
The result values (ees and eep) were expressed in a percentage using the following equations:
%ees ¼ R−SRþ S  100 ð4Þ
%eep ¼ R−SRþ S  100 ð5Þ
The C is
c ¼ ees
ees þ eep ð6Þ
The resolution values (Rs) is
Rs ¼ 2 tr2−tr1ð Þ
w1 þ w2ð Þ ð7Þ
where tr1 and tr2 are the retention times (in minutes) of the first and the last eluting peaks of a
pair, respectively; w1 and w2 are baseline widths (in minute) of these peaks.
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(R,S)-Flurbiprofen Esterification
The reaction mixture was composed of one of the solvent: MtBE, DCM, DCE, or DCP
(700 μL), and racemic flurbiprofen (4.8 mg, 0.02 mM) and one of the alcohols: methanol
(2.44 μL, 0.06 mM), ethanol (3.52 μL, 0.06 mM), n-propanol (4.51 μL, 0.06 mM), and n-
butanol (5.52 μL, 0.06 mM) as an acyl acceptor, and molecular sieve 4 Å (screening of lipases
was performed without addition of molecular sieves). The reaction was started by adding
8.75 mg lipase to the solution (1.5 mL glass tube). The suspensions were incubated at different
temperatures (20, 30, 37, and 45 °C) and shaken (600 rpm) in a thermomixer. Samples (50 μL)
were withdrawn at several time intervals. The collected samples were dried by evaporation at
room temperature and the residues redissolved in 0.9 mL IPA and, after filtration (0.45 μm),
injected (5 μL) on the HPLC column.
Results and Discussion
Analysis of (R,S)-Flurbiprofen and its Esters on Chiral Stationary Phases
Using the previously proposed methodology by Matthijs et al. [41] and optimization of the
chromatographic parameters on the four tested commercial polysaccharide-based CSPs, the
LC-3 column in normal-phase mode was selected for the enantioselective separation of (R,S)-
flurbiprofen and its esters (Fig. 1). The main aim of the optimization strategy was to obtain an
acceptable baseline resolution (Rs>1.5) of the compounds, analysis time, and peak shape.
Only LC-3 provided acceptable parameters of enantioseparation. The other three columns
(LC-1, LC-2, and LA-2) demonstrated a lower (Rs<1.5) or no (Rs=0) ability to resolve (R,S)-
flurbiprofen and its esters, long elution times, and inappropriate peak shapes. The optimized
mobile phase for LC-3 was composed of n-heptane/2-propanol/ trifluoroacetic acid (96.5/3.5/
0.2 v/v/v) at a flow rate of 1 mL/min. The normal-phase liquid chromatography (NPLC)
analyses were performed at a temperature of 15 °C. The tested compounds ((R,S)-flurbiprofen
and its esters) were eluted within 24 min and showed appropriate peak shapes and baseline
resolution (Rs>1.5).
Screening of Lipases
Commercially available lipases from C. rugosa (OF, MY, CRL) and C. antarctica (CAL-B and
Novozym 435) were tested for their catalytic properties of the enantioselective esterification of
racemic flurbiprofen with methanol as an alcohol in dichloropropane. The performed study
demonstrates the ability of several tested lipases to enantioselectively catalyze the esterification
of (R,S)-flurbiprofen (Table 1). Our study demonstrated that in case of C. antarctica lipase
application, (R)-flurbiprofen is the faster reacting enantiomer and is enantioselectively ester-
ified to the (R)-ester of flurbiprofen. However, the stereopreference of the lipase from
C. rugosa could not be proved due to the very low enantiomeric ratio of the esterification of
(R,S)-flurbiprofen catalyzed by this lipase in dichloropropane (Fig. 2).
Of all the tested lipases (Table 1), only CAL-B, Novozym 435, and OF showed catalytic
activity, whereas a lack of activity for the CRL and MY enzymes was observed. It should be
noted that the screening of lipases was performed without addition of molecular sieves. Their
application in the reaction catalyzed by lipase in the native (not immobilized) form causes a
significant reduction of enantiomeric ratio and conversion (data not shown), which has been
proven in our laboratory. Although none of the tested lipases showed enough high






























Fig. 1 HPLC chromatograms of (R,S)-flurbiprofen and its esters: a (R,S)-flurbiprofen and its methyl ester,
reaction time 96 h; b (R,S)-flurbiprofen and its ethyl ester, reaction time 120 h; c (R,S)-flurbiprofen and its n-
propyl ester, reaction time 96 h; d (R,S)-flurbiprofen and its n-butyl ester, reaction time 48 h; (R)-FMR-enantiomer
of methyl ester, (S)-FM S-enantiomer of methyl ester, (R)-FE R-enantiomer of ethyl ester, (S)-FE S-enantiomer of
ethyl ester, (R)-FP R-enantiomer of n-propyl ester, (S)-FP S-enantiomer of n-propyl ester, (R)-FB R-enantiomer
of n-butyl ester, (S)-FB S-enantiomer of n-butyl ester, (R)-F R-flurbiprofen, (S)-F S-flurbiprofen. Chromato-
graphic conditions: Lux Cellulose-3 (4.6 mm×250 mm×5 μm) column; mobile phase: n-heptane/2-propanol/
trifluoroacetic acid (96.5/3.5/0.2v/v/v), flow rate=1 mL/min, t=15 °C, UV=254 nm
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enantiomeric ratio (minimum for acceptable resolution is E>20 [46]), Novozym 435 was
selected for further research, based on the obtained results of C, ees, and eep.
Selection of the Reaction Medium
It is known that the conformation of enzymes strongly depends on the reaction medium
(solvents). Hence, the solvents have a meaningful impact on the activity of biocatalysts and
thus on the enantiomeric ratio and conversion of the enzymatic reactions. It is reported in the
literature [42] that due to the enzyme activity, enantioselective esterification with the use of
lipases should be conducted in hydrophobic solvents. Because of the low solubility of (R,S)-
flurbiprofen in commonly used hydrophobic solvents (e.g. isooctane, cyclohexane), other
alternative solvents DCM, DCE, DCP, and MtBE were applied in our study as reaction
medium. Results indicate (Table 2) that almost all performed esterification reactions in tested
solvents were enantioselective. After 20 h of incubation, the highest values of conversion (C=
55.5 %) and enantiomeric excess of substrate (ees=93.4 %) were achieved when the reaction
was carried out in DCP. However, the value of enantiomeric excess of product (eep) in this
medium was not satisfactory (eep=74.8 %). The enzymatic activity of Novozym 435 in DCE
also was high with enantiomeric ratio of the reaction E=62.7 and enantiomeric excess of the
product eep=94.7 %. The E-value after 330 h of incubation dramatically decreased when DCP
and MtBE were used as reaction medium. Also, the enantiomeric ratio of the reaction
conducted in DCE declined but remained above 20. Interestingly, the enantiomeric ratio of
the reaction performed in DCM for both time intervals was at high level (E=93.8 after 20 h
and E=109.1 after 330 h).
Moreover, the application of molecular sieves in the reaction significantly increased
enantiomeric ratio, as can be seen when comparing the results obtained at the stage of lipases
screening (Table 1) when Novozym 435 was tested without molecular sieves. The obtained
Table 1 Screening of lipases for the enantioselective esterification of (R,S)-flurbiprofen after (A) 24 h and (B)
330 h of the reaction
Time (h) Lipase ees (%) eep (%) C (%) E
A
24 CAL-B 6.0 84.9 6.5 13.0
24 Novozym 435 82.3 58.0 58.7 9.2
24 CRL − − − −
24 MY − − − −
24 OF 0.8 18.0 4.3 1.5
B
330 CAL-B 72.5 69.35 51.1 11.8
330 Novozym 435 48.0 2.7 94.6 1.4
330 CRL − − − −
330 MY − − − −
330 OF 4.0 26.0 13.25 1.8
Reaction conditions: racemic flurbiprofen (4.8 mg, 0.02 mM), methanol (2.44 μL, 0.06 mM), lipases (8.75 mg),
dichloropropane (700 μL), reaction temp 37 °C, shaking at 600 rpm
C conversion, ees enantiomeric excess of the substrate, eep enantiomeric excess of the product, E enantiomeric
ratio, (−) no reaction




































Fig. 2 HPLC chromatograms of (R,S)-flurbiprofen and its methyl esters after 24 h of the reaction: a with the use
of lipase from Candida rugosa OF; b with the use of lipase from C. rugosa MY; c with the use of lipase from
C. rugosa CRL; d with the use of lipase from Candida antarctica-Novozym 435; e with the use of lipase from
C. antarctica CAL-B. (R)-FM R-enantiomer of methyl ester, (S)-FM S-enantiomer of methyl ester, (R)-F R-
flurbiprofen, (S)-F S-flurbiprofen. Chromatographic conditions: Lux Cellulose-3 (4.6 mm×250 mm×5 μm)
column; mobile phase: n-heptane/2-propanol/trifluoroacetic acid (96.5/3.5/0.2v/v/v), flow rate=1 mL/min, t=
15 °C, UV=254 nm
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parameters of enzymatic activity lead to the conclusion that the addition of molecular sieves in
the reaction medium helps in maintaining a sufficient level of water content and provides
proper adsorption of water generated as a by-product during the esterification reaction. Water
plays a crucial role in the structure and function of enzymes because of its influence on their
active conformation. In addition, an inappropriate amount of water in the reaction medium
dramatically decreases the enantiomeric ratio and conversion of the reaction. Finally, because
of the promising reaction parameters, DCM was selected as an optimal solvent for further
studies on the enantioselective esterification of (R,S)-flurbiprofen.
Effect of Alcohol Moiety, Reaction Time, and Temperature
A number of studies showed that primary alcohols, because of the steric preferences, are the
most effective acyl acceptors in the enzymatic kinetic resolution of chiral acids (Scheme 1)
[24, 48]. Hence, the influence of the selected alcohols (methanol, ethanol, n-propanol, and n-
butanol) and the reaction time on the enantiomeric ratio and conversion of the esterification of
(R,S)-flurbiprofen in dichloromethane were tested. It is assumed that the accessibility of the
alcohol to the acyl-enzyme intermediate has significant impact on the final reaction yield and
enantiomeric ratio. Therefore, the nature of the alcohol moiety and its structure plays an
important role in the development of the enantioselective esterification reaction catalyzed by
lipase. The comparison of the enzymatic reaction parameters at a similar level of conversion
(Table 3) shows that with the increase of the carbon chain length of the studied alcohols, the E
of the reaction decreases. The best E-value (E=90.5) was obtained for methanol, whereas the
lowest one was seen when n-butanol (E=51.3) was used as an acyl acceptor. Curiously, the
esterification reactions of (R,S)-flurbiprofen catalyzed by Novozym 435 with all used alcohols
were significantly enantioselective (E-values in the range of 51.3–90.5), which showed the
stability of the catalyst in the reaction media with the tested alcohols. Because of the fact that
the active site of the enzyme has a hydrophobic character, it is believed that hydrophobic
alcohols are the most appropriate for esterification catalyzed by lipase. Furthermore, it is also
considered that the shorter polar alcohols, like methanol or ethanol, might cause a low
Table 2 Selection of solvent as reaction medium for kinetic resolution of (R,S)-flurbiprofen after (A) 20 h and
(B) 330 h of the reaction
Time (h) Solvent ees (%) eep (%) C (%) E
A
20 MtBE 46.6 84.7 35.5 19.2
20 DCP 93.4 74.8 55.5 23.5
20 DCE 52.3 94.7 35.6 62.7
20 DCM 16.7 97.5 14.6 93.8
B
330 MtBE 48.0 54.6 46.7 5.4
330 DCP 54.2 17.8 75.2 2.3
330 DCE 87.8 79.4 52.5 24.8
330 DCM 77.7 95.7 44.8 109.1
Reaction conditions: racemic flurbiprofen (4.8 mg, 0.02 mM), methanol (2.44 μL, 0.06 mM), Novozym 435
(8.75 mg), solvent (700 μL), molecular sieve 4 Å, reaction temp. 37 °C, shaking at 600 rpm
C conversion, ees enantiomeric excess of the substrate, eep enantiomeric excess of the product, E enantiomeric
ratio, MtBE methyl tert-butyl ether, DCP dichloropropane, DCE dichloroethane, DCM dichloromethane
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conversion because of their ability to dehydrate and denaturate the enzyme. The results of the
conversion reaction after 120 h of incubation were analyzed (37.1, 39.4, 42.8, 49.7 % in
methanol, ethanol, n-propanol, and n-butanol, respectively), and a correlation between the
carbon chain length of the alcohol and the final conversion was observed (Table 3, Fig. 3a).
These and the previous results allow confirming that with an increased number of carbon
atoms in the alcohols, there is an increase in the reaction rate [43].
Regarding the effect of the reaction time on C, it is observed that at each interval (24 h) of
sampling using methanol, ethanol, and n-propanol, C was increased at comparable rates, while
for n-butanol it was higher (Fig. 3a). Likewise, the values of enantiomeric excess of acid (ees)
were increased at different rates (Fig. 3b), but with a similar profile as run for C, and thus the
highest values were obtained using n-butanol. The enantiomeric excess of the product (eep) of
esterification when applying methanol (Table 3, Fig. 4) or ethanol as acyl acceptors remained
rather constant over time, while for n-propanol and n-butanol, eep slightly decreased over time.
The influence of temperature (Table 4) on the conversion and enantiomeric ratio of the
esterification of (R,S)-flurbiprofen was investigated at temperatures ranging from 20 to 45 °C.
It is well reported in the literature [48] that temperature has a pronounced effect on the enzyme
Scheme 1 The enantioselective esterification of racemic flurbiprofen with alcohols (methanol, ethanol, n-
propanol, and n-butanol) with the use of Novozym 435
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activity. Due to a better mass transfer and therefore an increased frequency of interactions
between substrates and enzyme, a higher temperature significantly contributes to the increased
catalytic activity of enzymes. However, an excessively high temperature can cause denatur-
ation of the protein structure [49]. The study showed that the conversion and enantiomeric
excess of the substrate (ees) increases with the increase of reaction temperature for all tested
alcohols. Comparing these values with a respect to the concerned acyl acceptors, there was
approximately almost twofold increase of C (23.2 and 40.4 % for methanol, 25.4 and 42.6 %
for ethanol, 25.0 and 43.3 % for n-propanol, 25.4 and 44.3 % for n-butanol) and more than
twofold increase of ees (29.0 and 64.4 % for methanol, 32.3 and 69.2 % for ethanol, 31.3 and
70.3 % for n-propanol, 32.1 and 73.2 % for n-butanol) between the lowest (20 °C) and the
highest (45 °C) temperature, respectively. The highest values of the described parameters were
obtained for n-butanol (C=44.3 % and ees=73.2 %) when the reaction was performed in
45 °C. A slight influence of the temperature was observed on the enantiomeric excess of
Table 3 Effect of alcohol moiety as an acyl acceptor (A) methanol, (B) ethanol, (C) n-propanol, and (D) n-
butanol and reaction time on the parameters of kinetic resolution of (R,S)-flurbiprofen
Time (h) ees (%) eep (%) C (%) E
A
24 24.1 96.7 20.0 77.2
48 37.2 96.6 27.8 84.2
72 45.0 96.1 31.9 77.4
96 53.6 96.3 35.7 90.5
120 56.5 95.6 37.1 79.8
B
24 19.5 96.2 16.8 63.1
48 33.7 95.8 26.0 65.4
72 43.1 95.7 31.1 69.6
96 53.1 95.5 35.7 74.5
120 62.1 95.3 39.4 78.7
C
24 14.5 96.5 13.1 65.7
48 30.2 95.2 24.1 54.1
72 43.1 94.4 31.3 53.4
96 56.7 93.9 37.7 56.3
120 69.5 92.3 42.8 55.6
D
24 25.2 95.4 21.0 53.8
48 49.7 94.0 34.6 53.0
72 65.5 92.6 41.4 51.3
96 78.9 91.4 46.3 53.8
120 88.3 89.4 49.7 52.7
Reaction conditions: racemic flurbiprofen (4.8 mg, 0.02 mM), methanol (2.44 μL, 0.06 mM), ethanol (3.52 μL,
0.06 mM), n-propanol (4.51 μL, 0.06 mM), n-butanol (5.52 μL, 0.06 mM), Novozym 435 (8.75 mg), dichlo-
romethane (700 μL), molecular sieve 4 Å, reaction temp. 37 °C, shaking at 600 rpm
C conversion, ees enantiomeric excess of the substrate, eep enantiomeric excess of the product, E enantiomeric
ratio
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product (eep), whose values marginally decreased at higher temperature. The application of
methanol allowed to obtain the highest value of eep (96.1 %) in reaction conducted at 37 °C,
and the lowest eep (91.8 %) was achieved when n-butanol in 45 °C was used. Summarizing the
results, the optimal temperature range for kinetic resolution, based on the conversion, eep, and
E-value is between 37 and 45 °C.
Taking into account the influence of alcohol moiety, reaction time, and temperature on the
enantioselective esterification of (R,S)-flurbiprofen, the global optimal conditions are charac-
terized by temperature in the range of 37–45 °C, application of methanol as an acyl acceptor,
and reaction time of 96 h (Fig. 1a).
In the literature, the investigation of Novozym 435- catalyzed kinetic resolution of (R,S)-
flurbiprofen by enantioselective esterification has been described. For example, A. Ghanem
[42] studied esterification of (R,S)-flurbiprofen in dichloromethane and obtained n-butyl ester
of (R)-flurbiprofen with the eep=91.3 % after 72 h of incubation. The E of the reaction was
25.8, C=14.6 % and ees=15.6 %. H.Y. Zhang et al. [50] tested esterification of (R,S)-
flurbiprofen with methanol as acyl acceptor in different solvents and achieved E of the reaction
in the range of 1.6–7.4. While in small scale-up of the reaction performed in medium



















































Fig. 3 Effect of reaction time a on the conversion and b on the enantiomeric excess of the substrate. Reaction
conditions: racemic flurbiprofen (4.8 mg, 0.02 mM), methanol (2.44 μL, 0.06 mM), ethanol (3.52 μL, 0.06 mM),
n-propanol (4.51 μL, 0.06 mM), n-butanol (5.52 μL, 0.06 mM), Novozym 435 (8.75 mg), dichloromethane
(700 μL), molecular sieve 4 Å, reaction temp. 37 °C, shaking at 600 rpm. C conversion, ees enantiomeric excess
of the substrate






















(R)-FM (S)-FM (R)-F (S)-F
Rs= 4.32
Rs=1.95
Fig. 4 HPLC chromatograms of racemic flurbiprofen and its methyl esters: a reaction time 24 h; b reaction time
48 h; c reaction time 72 h; d reaction time 120 h. (R)-FM R-enantiomer of methyl ester, (S)-FM S-enantiomer of
methyl ester, (R)-F R-flurbiprofen, (S)-F S-flurbiprofen. Chromatographic conditions: Lux Cellulose-3 (4.6 mm×
250 mm×5 μm) column; mobile phase: n-heptane/2-propanol/trifluoroacetic acid (96.5/3.5/0.2v/v/v), flow rate=
1 mL/min, t=15 °C, UV=254 nm
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were received. L. Tamborini et al. [10] obtained the following reaction parameters: ees=52 %,
eep=86 %, C=38 %, and E=22 for the esterification of (R,S)-flurbiprofen with n-butanol after
6 h of incubation in toluene in batch; whereas in a flow-chemistry reactor, after 15 min of the
reaction, the authors achieved the following values of the esterification: ees=50 %, eep=90 %,
C=36 % and E=31. R. Morrone et al. [51] carried out the esterification of (R,S)-flurbiprofen
with n-propanol and received enantiomeric ratio in the range of 1.0–22.2, depending on the
applied reaction medium. However, in a gram scale of esterification with methanol in
acetonitrile via a twofold kinetic resolution, (S)-flurbiprofen with ees>95 % was obtained.
All esterification reaction studies published in the above literature examples were performed in
different conditions. Comparing the described data with results in our article, it can be seen that
the received parameters for all tested alcohols are characterized by high value of
enantioselectivity–enantiomeric ratio in the range of 51.3–90.5 (Table 3). (R)-flurbiprofen
methyl ester as a product of enantioselective esterification was obtained with a high optical
purity eep=96.3 % after 96 h of incubation. The enantiomeric ratio of the reaction was 90.5,
the conversion was 35.7 %, and enantiomeric excess of the substrate, 53.6 %. Despite of
reported literature data describing enantioselective esterification of (R,S)-flurbiprofen with the
use of Novozym 435, the detailed optimization of the reaction conditions is still important area
Table 4 Influence of temperature on the parameters of enantioselective esterification of (R,S)-flurbiprofen with
(A) methanol, (B) ethanol, (C) n-propanol, and (D) n-butanol
Temperature (°C) ees (%) eep (%) C (%) E
A
20 29.0 95.8 23.2 62.0
30 35.0 96.0 26.7 70.6
37 45.0 96.1 31.9 77.4
45 64.4 95.0 40.4 77.0
B
20 32.3 94.5 25.4 49.0
30 40.3 94.0 30.0 47.7
37 43.1 95.7 31.1 69.6
45 69.2 93.2 42.6 59.3
C
20 31.3 94.2 25.0 45.6
30 40.0 94.0 29.8 49.8
37 43.1 94.4 31.3 53.4
45 70.3 92.1 43.3 51.3
D
20 32.1 94.4 25.4 47.2
30 52.5 94.0 35.8 53.7
37 65.5 92.6 41.4 51.3
45 73.2 91.8 44.3 51.7
Reaction conditions: racemic flurbiprofen (4.8 mg, 0.02 mM), methanol (2.44 μL, 0.06 mM), ethanol (3.52 μL,
0.06 mM), n-propanol (4.51 μL, 0.06 mM), n-butanol (5.52 μL, 0.06 mM), Novozym 435 (8.75 mg), dichlo-
romethane (700 μL), molecular sieve 4 Å, reaction temperature (20,30,37,45 °C), shaking at 600 rpm, reaction
time 72 h
C conversion, ees enantiomeric excess of the substrate, eep enantiomeric excess of the product, E enantiomeric
ratio
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of biotechnology, which allows to achieve high enzymatic activity and values of enantiomeric
ratio of the reaction.
Conclusions
In this study the lipases from C. rugosa and C. antarctica were tested for their application in
the enzymatic kinetic resolution of (R,S)-flurbiprofen by enantioselective esterification. The
screening of the enzymes allowed selecting Novozym 435 as the most appropriate biocatalyst
for obtaining products with high enantioselectivity.
It should be emphasized that well-resolved peaks of (R)- and (S)-flurbiprofen and their
esters in one chromatographic run on a Lux Cellulose-3 chiral stationary phase in normal
phase conditions were achieved. According to data [10, 42, 50, 51], obtained results of kinetic
resolution of (R,S)-flurbiprofen by enantioselective esterification using Novozym 435 for all
tested alcohols are characterized by high enantiomeric ratio (E in the range of 51.3–90.5).
Therefore, the performed enzymatic reactions have a great significance in the field of
biotechnological synthesis of drugs. As a result of optimization of the reaction conditions, it
was found that the best solvent for kinetic resolution of (R,S)-flurbiprofen with the use of
Novozym 435 was dichloromethane. All esterification reactions with the tested alcohols were
enantioselective, but the highest value of enantiomeric ratio was achieved when methanol was
applied. The optimal temperature to perform the reactions was in the range from 37 to 45 °C.
The proposed conditions were suitable to obtain (R)-flurbiprofen methyl ester with a high
optical purity eep=96.3 % after 96 h of incubation. The enantiomeric ratio of the reaction was
E=90.5, conversion C=35.7 %, and enantiomeric excess of substrate ees=53.6 %.
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